Episode
LCC in Italian: Resectable EGFR-mutant NSCLC
- Podcast
- Lung Cancer Considered
- Published
- May 8, 2026
- Duration seconds
- 2975
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/lung-cancer-considered-246259/episodes/lcc-in-italian-resectable-egfr-mutant-nsclc/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/lung-cancer-considered-246259/lcc-in-italian-resectable-egfr-mutant-nsclc.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Andrea Fillipi and Dr. Piergiorgio Solli. The tumor board focuses on the management of resectable EGFR-mutant NSCLC. Host: • Alfredo Addeo, MD Head of Oncology Service University Hospital Geneva Guests: Andrea R. Filippi, MD Head of Radiation Oncology, Fondazione Istituto Nazionale dei Tumori, Milan Associate Professor, Radiation Therapy Department of Oncology, University of Milan Piergiorgio Solli, MD, PhD Head of Thoracic Surgery IRCCS Fondazione Istituto Nazionale dei Tumori, Milan